The Evolving Global Landscape of Clinical Trials
The need to rapidly develop both a preventive and therapeutic intervention against COVID-19 has propelled the pharmaceutical industry into action.
The demand for the reduction in study build times requires agile adoption of technology, process, and resources. Speed, without impacting quality and regulatory requirements, has never been more critical. Sponsors and CROs alike are utilizing Medidata best-in-class technology and their rapid study build methodologies to shorten study builds from 14 weeks to just 4 weeks to ensure fast study starts without impacting quality.
In this Medidata NEXT Global session, Edward Ford, Senior Director of Client Engagement, together with Corey Harrison, Data Analyst, Catalyst Clinical Research, talk about utilizing Medidata Rave EDC and Rave Coder along with their study build expertise to expedite their COVID-19 studies.